Shares of Alcobra Ltd. (ADHD) tumbled 13.35% in pre-market trading Wednesday morning. The nosedive being attributed to results from the company’s Phase 2 clinical trial of MDX for Fragile X syndrome, a type of genetic disorder that could cause autism. The Israel-based Alcobra said the study did not meet primary endpoint. — Shares of Netflix, […] View the full post at: Morning Buzz: Alcobra Ltd. (ADHD), Netflix (NFLX), bluebird bio (BLUE), Juno (JUNO), Transition Therapeutics (TTHI) Related posts: Netflix (NFLX) Boosts Prize Economics Markets Flirting with Green Shoots to Brown Weeds Transition Dell Leads Transition of Laptop Displays to Energy-Efficient LED Technology